Silexion Therapeutics (SLXN) Competitors $0.76 -0.02 (-2.43%) Closing price 07/15/2025 03:59 PM EasternExtended Trading$0.76 +0.00 (+0.64%) As of 07/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. ENLV, COEP, TPST, NRSN, CVKD, CGTX, ALXO, CARA, TENX, and OVIDShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Enlivex Therapeutics (ENLV), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), Cognition Therapeutics (CGTX), ALX Oncology (ALXO), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors Enlivex Therapeutics Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics ALX Oncology Cara Therapeutics Tenax Therapeutics Ovid Therapeutics Silexion Therapeutics (NASDAQ:SLXN) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings. Which has more volatility & risk, SLXN or ENLV? Silexion Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Do analysts prefer SLXN or ENLV? Silexion Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 557.81%. Enlivex Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 713.01%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Silexion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media refer more to SLXN or ENLV? In the previous week, Silexion Therapeutics had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for Silexion Therapeutics and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 1.87 beat Silexion Therapeutics' score of 1.01 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Silexion Therapeutics Positive Enlivex Therapeutics Very Positive Which has better valuation and earnings, SLXN or ENLV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A-$16.44MN/AN/AEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.86 Do institutionals & insiders have more ownership in SLXN or ENLV? 11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 6.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SLXN or ENLV more profitable? Silexion Therapeutics' return on equity of 0.00% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -359.62% Enlivex Therapeutics N/A -57.67%-50.52% SummaryEnlivex Therapeutics beats Silexion Therapeutics on 9 of the 12 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.77M$2.96B$5.61B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.2228.5219.58Price / SalesN/A290.74426.1793.37Price / CashN/A43.1536.0257.93Price / Book-0.317.568.135.54Net Income-$16.44M-$55.11M$3.24B$257.73M7 Day Performance-16.46%3.81%0.20%-0.08%1 Month Performance-9.51%11.60%5.98%8.09%1 Year PerformanceN/A-2.11%26.15%13.02% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$0.76-2.4%$5.00+557.8%N/A$6.77MN/A0.00N/APositive NewsENLVEnlivex Therapeutics2.8436 of 5 stars$1.21+2.5%$10.00+726.4%-12.8%$27.91MN/A-1.8370COEPCoeptis Therapeutics0.396 of 5 stars$7.73+2.5%N/A+62.4%$26.49M$62.87K-1.332TPSTTempest Therapeutics2.3404 of 5 stars$7.08-0.7%$30.00+323.7%-76.8%$26.26MN/A-0.3920Positive NewsNRSNNeuroSense Therapeutics2.4602 of 5 stars$2.09+9.4%$14.00+569.9%+114.3%$26.10MN/A-3.8710CVKDCadrenal Therapeutics2.9339 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404CGTXCognition Therapeutics2.9299 of 5 stars$0.58+42.9%$2.83+389.5%-70.4%$25.11MN/A-0.7820High Trading VolumeALXOALX Oncology3.5425 of 5 stars$0.44-3.5%$3.30+643.2%-94.2%$24.57MN/A-0.1840Gap DownCARACara Therapeutics0.2178 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.6682 of 5 stars$5.75-1.0%$17.50+204.3%+77.1%$24.10MN/A-2.329Positive NewsOVIDOvid Therapeutics4.6389 of 5 stars$0.37+10.5%$3.13+735.6%-60.8%$24.06M$570K-1.0760High Trading Volume Related Companies and Tools Related Companies Enlivex Therapeutics Alternatives Coeptis Therapeutics Alternatives Tempest Therapeutics Alternatives NeuroSense Therapeutics Alternatives Cadrenal Therapeutics Alternatives Cognition Therapeutics Alternatives ALX Oncology Alternatives Cara Therapeutics Alternatives Tenax Therapeutics Alternatives Ovid Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLXN Stock Alerts